Christopher Young to Succeed David DeStefano as Vertex’s President and Chief Executive OfficerLeadership Transition to Occur on November 10, ...

Christopher Young to Succeed David DeStefano as Vertex's President and Chief Executive Officer Leadership Transition to Occur on November 10, 2025; David DeStefano to Serve as Non-Executive Chairperso ...

Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...

30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data ...

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today ...

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery ...

PRINCETON, N.J., October 13, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for ...

MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data ...

Announces 2025 Third Quarter Earnings. MESSAGE FROM OUR CHAIRMAN & CEO We continued to optimize our balance sheet to be more efficient and profitable with adjusted return on average assets (2) ...

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...

BeOne Medicines (ONC) announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA, or ...